Cargando…

Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease

BACKGROUND/AIMS: Though nocturnal acid-breakthrough (NAB) is common in gastroesophageal reflux disease (GERD) patients, its clinical importance results from esophageal acidification, which has been shown to be uncommon. Ilaprazole, a long-acting proton pump inhibitor, may cause NAB infrequently. Acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Karyampudi, Arun, Ghoshal, Uday C, Singh, Rajan, Verma, Abhai, Misra, Asha, Saraswat, Vivek A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Neurogastroenterology and Motility 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383115/
https://www.ncbi.nlm.nih.gov/pubmed/27585842
http://dx.doi.org/10.5056/jnm16087
_version_ 1782520223943884800
author Karyampudi, Arun
Ghoshal, Uday C
Singh, Rajan
Verma, Abhai
Misra, Asha
Saraswat, Vivek A
author_facet Karyampudi, Arun
Ghoshal, Uday C
Singh, Rajan
Verma, Abhai
Misra, Asha
Saraswat, Vivek A
author_sort Karyampudi, Arun
collection PubMed
description BACKGROUND/AIMS: Though nocturnal acid-breakthrough (NAB) is common in gastroesophageal reflux disease (GERD) patients, its clinical importance results from esophageal acidification, which has been shown to be uncommon. Ilaprazole, a long-acting proton pump inhibitor, may cause NAB infrequently. Accordingly, we studied prospectively, (1) frequency and degree of esophageal acidification during NAB, and (2) frequency and severity of NAB while on ilaprazole versus omeprazole. METHODS: Fifty-eight consecutive patients with GERD on once daily ilaprazole, 10 mg (n = 28) or omeprazole, 20 mg (n = 30) for > one month underwent 24-hour impedance-pH monitoring prospectively. NAB was defined as intra-gastric pH < 4 for > one hour during night, and esophageal acidification as pH < 4 for any duration. Nocturnal symptoms (heartburn, regurgitation, and chest pain) were also recorded. RESULTS: Of the 58 patients (age 35.5 [inter-quartile range 26.5–46.0] years, 38 [65.5%], 42 (72.4%) had NAB. Though patients with NAB had lower nocturnal intra-gastric pH than without (2.8 [1.9–4.1] vs 5.7 [4.6–6.8], P < 0.001), frequency and duration of nocturnal esophageal acidification (17/42 vs 4/16, P = 0.360 and 0.0 [0.0–1.0] vs 0.0 [0.0–0.3] minutes, P = 0.260, respectively) and symptoms were comparable (13/42 vs 6/16, P = 0.750). Though ilaprazole was associated with less NABs (1 [range 1–2, n = 19] vs 1 [range 1–3, n = 23], P = 0.010) than omeprazole, the frequency, duration, and mean intra-gastric pH during NAB were comparable (19/28 vs 23/30, P = 0.560; 117 [0–315] vs 159 [69–287] minutes, P = 0.500; 1.02 [0.7–1.4] vs 1.04 [0.44–1.3], P = 0.620, respectively). CONCLUSIONS: Though NAB was common while patients were on a proton pump inhibitor, esophageal acidification was uncommon. Frequency and severity of NAB were comparable among patients on ilaprazole and omeprazole, except for the lesser number of NABs with ilaprazole.
format Online
Article
Text
id pubmed-5383115
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-53831152017-04-07 Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease Karyampudi, Arun Ghoshal, Uday C Singh, Rajan Verma, Abhai Misra, Asha Saraswat, Vivek A J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Though nocturnal acid-breakthrough (NAB) is common in gastroesophageal reflux disease (GERD) patients, its clinical importance results from esophageal acidification, which has been shown to be uncommon. Ilaprazole, a long-acting proton pump inhibitor, may cause NAB infrequently. Accordingly, we studied prospectively, (1) frequency and degree of esophageal acidification during NAB, and (2) frequency and severity of NAB while on ilaprazole versus omeprazole. METHODS: Fifty-eight consecutive patients with GERD on once daily ilaprazole, 10 mg (n = 28) or omeprazole, 20 mg (n = 30) for > one month underwent 24-hour impedance-pH monitoring prospectively. NAB was defined as intra-gastric pH < 4 for > one hour during night, and esophageal acidification as pH < 4 for any duration. Nocturnal symptoms (heartburn, regurgitation, and chest pain) were also recorded. RESULTS: Of the 58 patients (age 35.5 [inter-quartile range 26.5–46.0] years, 38 [65.5%], 42 (72.4%) had NAB. Though patients with NAB had lower nocturnal intra-gastric pH than without (2.8 [1.9–4.1] vs 5.7 [4.6–6.8], P < 0.001), frequency and duration of nocturnal esophageal acidification (17/42 vs 4/16, P = 0.360 and 0.0 [0.0–1.0] vs 0.0 [0.0–0.3] minutes, P = 0.260, respectively) and symptoms were comparable (13/42 vs 6/16, P = 0.750). Though ilaprazole was associated with less NABs (1 [range 1–2, n = 19] vs 1 [range 1–3, n = 23], P = 0.010) than omeprazole, the frequency, duration, and mean intra-gastric pH during NAB were comparable (19/28 vs 23/30, P = 0.560; 117 [0–315] vs 159 [69–287] minutes, P = 0.500; 1.02 [0.7–1.4] vs 1.04 [0.44–1.3], P = 0.620, respectively). CONCLUSIONS: Though NAB was common while patients were on a proton pump inhibitor, esophageal acidification was uncommon. Frequency and severity of NAB were comparable among patients on ilaprazole and omeprazole, except for the lesser number of NABs with ilaprazole. Korean Society of Neurogastroenterology and Motility 2017-04 2017-04-01 /pmc/articles/PMC5383115/ /pubmed/27585842 http://dx.doi.org/10.5056/jnm16087 Text en © 2017 The Korean Society of Neurogastroenterology and Motility This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Karyampudi, Arun
Ghoshal, Uday C
Singh, Rajan
Verma, Abhai
Misra, Asha
Saraswat, Vivek A
Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
title Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
title_full Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
title_fullStr Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
title_full_unstemmed Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
title_short Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
title_sort esophageal acidification during nocturnal acid-breakthrough with ilaprazole versus omeprazole in gastroesophageal reflux disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383115/
https://www.ncbi.nlm.nih.gov/pubmed/27585842
http://dx.doi.org/10.5056/jnm16087
work_keys_str_mv AT karyampudiarun esophagealacidificationduringnocturnalacidbreakthroughwithilaprazoleversusomeprazoleingastroesophagealrefluxdisease
AT ghoshaludayc esophagealacidificationduringnocturnalacidbreakthroughwithilaprazoleversusomeprazoleingastroesophagealrefluxdisease
AT singhrajan esophagealacidificationduringnocturnalacidbreakthroughwithilaprazoleversusomeprazoleingastroesophagealrefluxdisease
AT vermaabhai esophagealacidificationduringnocturnalacidbreakthroughwithilaprazoleversusomeprazoleingastroesophagealrefluxdisease
AT misraasha esophagealacidificationduringnocturnalacidbreakthroughwithilaprazoleversusomeprazoleingastroesophagealrefluxdisease
AT saraswatviveka esophagealacidificationduringnocturnalacidbreakthroughwithilaprazoleversusomeprazoleingastroesophagealrefluxdisease